UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.68 USD | +2.41% |
|
+3.08% | -30.87% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
| Sales 2024 * | 55.57M 59.72M | Sales 2025 * | 78.26M 84.1M | Capitalization | 212M 228M |
|---|---|---|---|---|---|
| Net income 2024 * | -202M -217M | Net income 2025 * | -182M -196M | EV / Sales 2024 * | 2.81 x |
| Net cash position 2024 * | 55.78M 59.94M | Net cash position 2025 * | 50.83M 54.63M | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-1.23
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | +2.41% | ||
| 1 week | +3.08% | ||
| Current month | +6.12% | ||
| 1 month | -6.02% | ||
| 3 months | -13.17% | ||
| 6 months | -18.18% | ||
| Current year | -30.87% |
1 week
4.25
4.71
1 month
4.255.48
Current year
4.257.12
1 year
4.2522.48
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 16 M€ | -4.51% | ||
| 0.48% | 29 M€ | -3.51% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 4.68 | +2.41% | 391,694 |
| 24-05-01 | 4.57 | +3.63% | 696,984 |
| 24-04-30 | 4.41 | +0.46% | 503,256 |
| 24-04-29 | 4.39 | -3.09% | 827,154 |
| 24-04-26 | 4.53 | -0.22% | 354,544 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.374
EUR
Average target price
18.98
EUR
Spread / Average Target
+333.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.87% | 227M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +6.70% | 23.07B | |
| -12.60% | 22.23B | |
| -5.24% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- QURE Stock
